# Amplicore

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amplicore

- Industry: Biotechnology
- Headquarters: Mason, US
- Website: www.amplicorepharma.com
- Total disclosed funding: $4M
- Latest round: Seed (Mar 25, 2021)
- Investors on record: 4

## About

Amplicore, Inc., based in Mason, Ohio, specializes in developing injectable therapeutics for degenerative musculoskeletal disorders, including osteoarthritis and cartilage damage, founded in 2019.Amplicore, Inc. focuses on innovative therapies for musculoskeletal conditions. Founded by Chia-Ying Lin, the company has secured its position in the medical field with a single deal recorded on March 25, 2021, when it raised USD 4 million in a SEED round led by Photon Fund, alongside investors like Berkeley Catalyst Fund, Industrial Technology Investment Corporation, and SVE Capital. This funding has supported the advancement of their treatments for joint disorders.Amplicore specializes in the development of injectable therapeutics aimed at treating degenerative musculoskeletal disorders, specifically targeting conditions such as osteoarthritis, cartilage damage, degenerative disc disease, and acute meniscus tears. Their primary offerings, AM1101 for osteoarthritis and AM3101 for meniscal repair, are designed utilizing a regenerative approach that relieves pain while addressing the underlying causes of joint discomfort. These products are positioned to meet the unmet medical needs of patients suffering from these conditions, marketed primarily in the United States, with potential expansions into other regions where similar medical needs exist.Amplicore generates revenue through direct sales of its injectable therapeutics to healthcare providers, hospitals, and clinics specializing in orthopedics and pain management. The transaction structure follows a Business-to-Business (B2B) model, where healthcare facilities purchase Amplicore's products to integrate them into their treatment protocols. Revenue streams are bolstered through strategic partnerships with medical organizations and possibly distributors, although specific pricing details for AM1101 and AM3101 remain undisclosed.Amplicore plans to utilize its recent funding, raised on March 25, 2021, to complete the preclinical development of AM3101 and AM1101. In addition to advancing these products, the company aims to explore opportunities for expansion into new geographic markets, enhancing its reach to a broader clientele by targeting regions with high demand for innovative musculoskeletal treatments.

## Funding rounds

- Seed, Mar 25, 2021, $4M — Industrial Technology Investment Corporation, Photon Fund, Berkeley Catalyst Fund, SVE Capital

## Investors

- Industrial Technology Investment Corporation (https://capitalatlas.ai/funds/industrial-technology-investment-corporation) — Seed
- Photon Fund (https://capitalatlas.ai/funds/photon-fund) — Seed
- Berkeley Catalyst Fund (https://capitalatlas.ai/funds/berkeley-catalyst-fund) — Seed
- SVE Capital (https://capitalatlas.ai/funds/sve-capital) — Seed